Herman Mielants
About
In The Last Decade
Herman Mielants
208 papers receiving 10.4k citations
Hit Papers
Peers
Comparison fields: 5 of 126
- Rheumatology 8.6k
- Immunology 4.9k
- Hematology 3.3k
- Genetics 1.6k
- Epidemiology 1.1k
Countries citing papers authored by Herman Mielants
This map shows the geographic impact of Herman Mielants's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Herman Mielants with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Herman Mielants more than expected).
Fields of papers citing papers by Herman Mielants
This network shows the impact of papers produced by Herman Mielants. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Herman Mielants. The network helps show where Herman Mielants may publish in the future.
Co-authorship network of co-authors of Herman Mielants
This figure shows the co-authorship network connecting the top 25 collaborators of Herman Mielants. A scholar is included among the top collaborators of Herman Mielants based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Herman Mielants. Herman Mielants is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | A nationwide survey on patient's versus physician's evaluation of biological therapy in rheumatoid arthritis in relation to disease activity and route of administration: the Be-Raise study | 1 |
| 2 | Agreement between evidence and Belgian rheumatologists' experience on the use of DMARDs for arthritis and/or enthesitis in ankylosing spondylitis | 2 |
| 3 | Four year follow-up of infliximab in rheumatoid arthritis patients refractory to multiple dmard treatment: Long-term clinical effect and prediction of attrition. | 1 |
| 4 | Four year follow-up of infliximab in rheumatoid arthritis patients refractory to multiple dmard treatment: Attrition and long-term clinical effect | 1 |
| 5 | Belgian patients with familial and sporadic ankylosing spondylitis differ in disease phenotype | 2 |
| 6 | Bowel inflammation in rheumatic diseases: Trigger or consequence | 1 |
| 7 | Preliminary evidence for a retardation of structural damage in patients with ankylosing spondylitis continuously treated with infliximab for 4 years | 1 |
| 8 | Short and long term synovial immunumodulation by etanercept in spondyloarthropathy | 1 |
| 9 | The SF-6D differentiates less in the lower ranges of the patient's utility when compared with the EQ-5D but has a better reliability and sensitivity to change | 1 |
| 10 | 11 | |
| 11 | 9 | |
| 12 | T cell cytokines in gut mucosa of patients with spondyloarthropathy reflect immune alterations in Crohn's disease | 3 |
| 13 | 6 | |
| 14 | Gastrointestinal tract and rheumatic disease | 1 |
| 15 | Ileitis in the spondylarthropathies | 1 |
| 16 | Clinical aspects of enterogenic arthropathies | 1 |
| 17 | 2nd Conference on spondylarthropathies and the gut, Gent, Belgium, 1-2 July 1993 | 2 |
| 18 | Destructive hip lesions in seronegative spondyloarthropathies: relation to gut inflammation. | 13 |
| 19 | 26 | |
| 20 | 19 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.